Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 10Neuroendocrine Tumors 7Neoplasm Metastasis 7Recurrence 4Tuberous Sclerosis 3Triple Negative Breast Neoplasms 3Neoplasms 3Kidney Neoplasms 3Endometrial Neoplasms 3von Hippel-Lindau Disease 2Skin Neoplasms 2Sarcoma 2Meningioma 2Glioma 2Gastro-enteropancreatic neuroendocrine tumor 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Adenoma, Islet Cell 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1

Interventions

Alpelisib 2mirdametinib 1Sirolimus 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioma × Everolimus × 1 year × Clear all
NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Yonsei University

Phase 2 Not yet recruiting
67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡